COVID-19 spike variants antigen Recombinant 2019-nCoV(SARS-CoV-2) P.1 lineage(B.1.1.28.1, Brazilian variant) Spike RBD Protein(K417T, E484K and N501Y mutant) Spike RBD Protein(K417T, E484K and N501Y mutant)

Cat No.: GMP-V-2019nCoV-Smu-016

Order information

Package Catalog No. Price(In USD) Qty (Quantity) Sum(In USD)
1mg GMP-V-2019nCoV-Smu-016-1mg 5990
10mg GMP-V-2019nCoV-Smu-016-10mg 38790
100mg GMP-V-2019nCoV-Smu-016-100mg 258000
≥100mg GMP-V-2019nCoV-Smu-016-xmg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Accession Number QHD43415.1
Expression platform 2019-nCoV(SARS-CoV-2, SARS2-coronavirus)
IsotypesMamamlian (human cell)
TagC-His
Products descriptionRecombinant 2019-nCoV(SARS-CoV-2)-P.1 lineage(B.1.1.28.1, Brazilian variant) receptor binding domain (RBD) from the Spike Protein (S protein) with K417T, E484K and N501Y mutation was expressed in mammanlian cell (human cells) expression system with 6 HIS tag at the C-terminus.
Bioactivity validation ACE2 binding;
Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays;
PurityPurity: ≥95% (SDS-PAGE)
ApplicationSpike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies.
Immunogen in Elisa,lateral-flow tests,and other immunoassays;
Standard substance
The antigen can also be used in drug discovery including antibody screening and lead compound candidates assay.
predicted Molecular Mass35kDa
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

COVID-19 recombinant SARS-CoV2 (2019 nCoV coronavirus)antigen:
Recombinant 2019-nCoV(SARS-CoV-2) P.1 lineage(B.1.1.28.1, Brazilian variant) Spike RBD Protein(K417T, E484K and N501Y mutant)

Suitable for variants of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies. Validated in functional ELISA, other immunoassays, the antigen can also be used in drug discovery including antibody screening and lead compound candidates assay.